Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Optomed Plc is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. The company operates in two segments: Devices, which develops, manufactures, and commercializes easy-to-use handheld fundus cameras for screening eye diseases like diabetic retinopathy, glaucoma, and age-related macular degeneration; and Software, which provides AI-powered solutions such as Avenue AI, Avenue Eye Screen, and Avenue Flow for workflow management, telemedicine, and disease monitoring. Notable products include Optomed Smartscope Pro, Aurora, and Polaris brands, alongside OEM cameras for partners like Volk Optical, Carl Zeiss Meditec, and Topcon. Optomed integrates artificial intelligence and explores oculomics to detect systemic conditions via retinal imaging, enhancing early diagnosis in ophthalmology, primary care, and beyond. With over 100 employees, headquarters in Oulu, Finland, and subsidiaries in the US and China, it sells through distributors, OEMs, and direct channels in over 60 countries, playing a pivotal role in making eye screening accessible globally and advancing preventive healthcare through portable, AI-driven diagnostics.
€1.67
€0.08 (-4.36%)
EOD Jul 2, 2026
The business is unprofitable at the operating level (-35.34% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 13.7% YoY with margins expanding 4.3pp.
Negative free cash flow of -€5M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€16M
▲ +13.7% YoY
Net Income (TTM)
-€6M
▼ -21.8% YoY
Op. Margin
-36.95%
▲ +4.3pp YoY
ROIC
-17.62%
▲ +0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€6M
▼ -30.3% YoY
Op. Cash Flow (TTM)
-€5M
▼ -24.4% YoY
Net Debt
-€7M
Net Cash Position
Cash & Equiv.
€10M
3Y CAGR: +5.3%
Continue Research
Optomed (OPTOMED.XHEL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Optomed scores 18/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Optomed scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -36.9% operating margin and a -17.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh OPTOMED.XHEL's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.